Dr. Joel Hay, PhD, is Associate Professor of Pharmaceutical Economics and Policy at USC and a health economist with the Rand Corporation and the UCLA Center for Vaccine Research. He has received the Research Excellence Award from the International Society for Pharmacoeconomics and Outcomes Research and has consulted internationally, including the Hong Kong Hospital Authority and the Hungarian Parliament. He is currently involved in three ongoing NIH research grants on patient-centered care in the public sector and depression in medical illness.
Positions & HonorsPositions
|2001-present||Health Economist, UCLA Center for Vaccine Research, UCLA Harbor Medical Center, Torrance, CA|
|1997-present||Health Economist, The Rand Corporation Health Outcome Research Group, Santa Monica, CA|
|2009-present||Full Professor, Department of Pharmaceutical Economics and Policy and Department of Economics, University of Southern California School of Pharmacy|
|1992-2009||Associate Professor, Department of Pharmaceutical Economics and Policy and Department of Economics, University of Southern California School of Pharmacy|
|1992-2009||Associate Professor, Department of Economics, USC School of Letters, Los Angeles, CA|
|1985-1992||Senior Research Fellow, Hoover Institution, Stanford University, Palo Alto, CA|
Selected Honors & Awards
|2004-present||Scientific Advisory Board, Disease Management Association of America|
|2004-present||Member, Health Science Policy Council, International Society for Pharmacoeconomics and Outcomes Research|
|2004-present||Board of Directors & Founding Member, American Society for Health Economics|
|2002||Distinguished Service Award, Intl Soc for Pharmacoeconomics and Outcomes Research|
|2002||Institute of Medicine. Commissioned Author "Vaccine Reimbursement Policy in the US." Washington, DC|
|1998-2002||Editor-in-chief, Value in Health, Journal of ISPOR. Princeton, NJ|
|1998-1999||Research Excellence Award, Intl Soc for Pharmacoeconomics and Outcomes Research|
|Yale University, New Haven||Ph.D.||1980||Economics|
|Yale University, New Haven||M.Phil.||1976||Economics|
|Yale University, New Haven||M.A.||1975||Economics|
|Amherst College, MA||B.A.||1974||Economics/Mathematics|
Current Research Support
1R01 HD056267-01A1 Clark (PI) 9/1/08-7/31/2013
National Institute on Aging (NIA)
Lifestyle Redesign for Pressure Ulcer Prevention in SCI
To conduct an RCT of a lifestyle redesign intervention’s ability to reduce medically serious (Stage 3 or 4) pressure ulcers in adults with SCI. To assess the cost-effectiveness and potential cost savings of the intervention. To examine the intervention’s effects on the participants’quality of life. To model the intervening process mechanisms that mediate the effects of the intervention.
MH068639-0 (Lagomasino) 9/2004-6/2009
National Institute of Health, NIMH
Self-Management of Depression and Medical Illness
Research center aims to improve the delivery of health services for persons with psychiatric disorders through community-based research. Subcontract aims to develop mental health services interventions in public systems of care.
R01 MH068468-01A2 (Ell) 7/2004-9/2009
National Institute of Health, NCI
Multifaceted Depression Program for Pregnant Women
This is a randomized clinical trial to test the effectiveness of health services quality improvement intervention, Multi-faceted Depression and Diabetes Program (MDDP), on improvement in depressive symptoms over time, patient adherence to diabetes self-care regimens, glycemic control, functional status, and quality of life among low-income Hispanic adults with diabetes.
- Zeiger R, Hay J, Contreras R, Chen W, Quinn V, Seal B, Schatz M, (2008) “Risk-Stratified Medical Costs for Asthma Patients in a Managed Care Organization (MCO).” J Allergy and Clinical Immunology. 121:885-92.
- Hay J, Rindress D, Editors. Disease Management Principles and Practices: The Current State of the Art. (2007) Disease Management Association of America, Washington, DC.
- Liou, S.Y., Stephens, J.M., Carpiuc, K.T., Feng, W., Botteman, M. F., & Hay, J. (2007). Economic burden of haematological adverse effects in cancer patients: A systematic review. Clin Drug Investig, 27(6), 381-396.
- Hay, J. (2006). Where’s the Value in Health Care? Value in Health, 9(2), 11-14.
- Stephens, J.M., Botteman, M.F., & Hay, J. (2006). Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. Journal of Managed Care Pharmacy, 12(2), 130-142.
- Spalding, J. & Hay, J. (2006). Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006; 24:1221-1232.
- Spalding J, Hay J. Cost-Effectiveness of TNF Alpha Inhibitors in RA. Pharmacoeconomics (2006) 24:1221-32.
- Hay, J.W. & Leahy, M. (2005). Cost and utilization impacts of oral antihistamines in the California Medi-Cal program. Value in Health, 8, 506-516.
- Hay, J.W. & Sterling, K.L. (2005). Cost effectiveness of treating low HDL cholesterol in the primary prevention of coronary heart disease.Pharmacoeconomics, 23, 133-141.
- Narayan, S. & Hay, J. (2004). Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Review of Pharmacoeconomics and Outcomes Research, 4, 625-634.
- Purdy, K.W., Hay, J.W., Botteman, M.F., & Ward, J.I. (2004). Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clinical Infectious Diseases, 39, 20-28.
- Dwight-Johnson, M., Lagomasino, I.T., Aisenberg, E. & Hay, J. (2004). Using conjoint analysis to assess depression treatment preferences among low-income Latinos. Psychiatric Services, 55, 934-936.
- Chen, L. & Hay, J.W. (2004). Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovascular Drugs & Therapy, 18, 161-170.